TB Sequel - Study of the clinical, microbiological and immunological factors leading to unfavorable pulmonary "outcome" in TB patients.

In general, the activities planned in this project serve to consolidate the achieved scientific and technical goals of the TB Sequel study and the TB Sequel network, as well as to further develop them in preparation for the planned application for a second funding period from 2023-2027. Another focus of this application is the integration and funding of measures that address the new epidemiological situation caused by the Covid 19 pandemic. In order to achieve the objectives of the project, the main focus of activities will be on the maintenance of the TB Sequel Cohort. This will be done by continuing the follow-up in 2022 with at least one physical study visit and one additional phone call. At both visits, the most relevant morbidity and mortality data and soc-econ. data with respect to the outcomes studied in TB Sequel to date will be collected. Data will be collected (and clinical samples taken) and either analysed in conjunction with TB Sequel data (2017-2021) or processed and published as part of a stand-alone analysis. In addition to the continuation of the cohort, the coordinators or various investigators of Research Tasks 1-5 will also conduct new studies and investigations that have a completely new aspect to the research subject (e.g. interaction between TB and Covid-19), but are relevant to specific questions in the new funding period, or serve to directly prepare the further funding period (e.g. review and interviews on local infrastructures regarding the future treatment and therapy of patients with post-TB lung disease).